Paratek is developing NUZYRA® (omadacycline) in an investigational Phase 2 study currently in process (NCT03425396) to evaluate the safety, tolerability and pharmacokinetics of NUZYRA in female patients with uncomplicated UTI. Paratek is also conducting a second Phase 2 study currently in progress (NCT03757234) to evaluate the safety, tolerability and pharmacokinetics of NUZYRA in female patients with acute pyelonephritis. Topline data from both studies are expected in the second half of 2019.
Under a research agreement with the U.S. Department of Defense, NUZYRA is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.
Paratek owns world-wide rights to omadacycline. Paratek has entered into a collaboration with Zai Lab (Shanghai) Co., Ltd., a biopharmaceutical company based in China, to support the development and commercialization of omadacycline for patients in Greater China.
Paratek is open to discussing partnerships for rights in other regions with interested parties. Please contact us here.
The FDA approved SEYSARA® (sarecycline) in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. SEYSARA is marketed by Almirall, LLC in the U.S. For complete prescribing information, including the Warnings and Precautions, please visit here.
Paratek has retained rest of world (outside of the U.S.) rights to sarecycline and is currently exploring partnership opportunities to develop and approve sarecycline in appropriate markets. Please contact us here.